このページの翻訳は実験的なもので、現在開発中です。お待ちしております

PetMed Express マネジメント

マネジメント基準チェック /14

PetMed Express'の CEO はSandra Camposで、 Apr2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.008%を直接所有しており、その価値は€ 6.50K 。経営陣と取締役会の平均在任期間はそれぞれ0.2年と2.2年です。

主要情報

Sandra Campos

最高経営責任者

US$128.2k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.008%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	1.9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Sandra Campos (57 yo)

less than a year

在職期間

US$128,183

報酬

Ms. Sandra Y. Campos is Independent Director of PetMed Express, Inc. from May 17, 2023 and serves as its CEO and President since April 29, 2024. She serves as an Independent Director at Commerce Fabric, In...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sandra Campos	President	less than a year	US$128.18k	0.0079% $ 5.3k
Christine Chambers	Treasurer & Secretary	1.9yrs	US$401.34k	0.082% $ 55.8k
Robyn DElia	Chief Financial Officer	no data	データなし	データなし
Caroline Conegliano	Chief Operating Officer	less than a year	データなし	データなし
Doug Krulik	Chief Accounting Officer	less than a year	データなし	データなし
Mark Moseley	Chief Technology & Information Officer	2.7yrs	データなし	0.20% $ 138.4k
Carla Dodds	Chief Marketing Officer	less than a year	データなし	データなし
Jacqueline Smith	Vice President of People	2.7yrs	データなし	0.066% $ 45.0k
Umesh Sripad	Chief Digital & Technology Officer	less than a year	データなし	データなし
Wendy Zalai	Corporate Controller & Corporate Secretary	3.6yrs	データなし	データなし

0.4yrs

平均在職期間

経験豊富な経営陣: PQMの経営陣は経験豊富とはみなされません ( 0.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Sandra Campos	President	1.3yrs	US$128.18k	0.0079% $ 5.3k
Gian Fulgoni	Independent Director	21.8yrs	US$150.98k	0.55% $ 369.2k
Diana Purcel	Independent Director	2.4yrs	US$139.53k	0.058% $ 39.1k
Leah Solivan	Independent Director	less than a year	データなし	データなし
Leslie C. Campbell	Independent Chairman of the Board	6.2yrs	US$143.07k	0.21% $ 140.1k
Justin Mennen	Independent Director	less than a year	データなし	データなし

1.9yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: PQMの取締役会は経験豊富ではない ( 2.2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

PetMed Express マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

PetMed Express, Inc. Appoints Robyn DElia as Chief Financial Officer, Effective September 16, 2024

Petmed Express, Inc. Appoints Doug Krulik as Chief Accounting Officer, Effective August 19, 2024

PetMed Express, Inc., Annual General Meeting, Aug 08, 2024

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors

PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024

PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer

Recent updates

Now 21% overvalued

PetMed Express, Inc. Appoints Robyn DElia as Chief Financial Officer, Effective September 16, 2024

New major risk - Revenue and earnings growth

First quarter 2025 earnings released: EPS: US$0.18 (vs US$0.056 loss in 1Q 2024)

Now 28% overvalued

Petmed Express, Inc. Appoints Doug Krulik as Chief Accounting Officer, Effective August 19, 2024

PetMed Express, Inc. to Report Q1, 2025 Results on Aug 06, 2024

PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000 Index

PetMed Express, Inc., Annual General Meeting, Aug 08, 2024

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors

Full year 2024 earnings released: US$0.37 loss per share (vs US$0.25 profit in FY 2023)

New major risk - Revenue and earnings growth

PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024

PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer

PetMed Express, Inc. to Report Q4, 2024 Results on Jun 11, 2024

PetMed Express, Inc. Appoints Justin Mennen to Board of Directors, Effective June 3, 2024

PetMed Express, Inc. Announces Executive Changes

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought €281k worth of stock

CEO, President & Director recently bought €94k worth of stock

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.13 profit in 2Q 2023)

PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: US$0.044 loss per share (vs US$0.14 profit in 1Q 2023)

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

High number of new directors

Full year 2023 earnings released: EPS: US$0.011 (vs US$1.05 in FY 2022)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on June 12, 2023

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

PetMed Express, Inc. to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.21 profit in 3Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on February 27, 2023

Investor sentiment improves as stock rises 17%

PetMed Express, Inc. to Report Q3, 2023 Results on Feb 06, 2023

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

Second quarter 2023 earnings released: EPS: US$0.13 (vs US$0.32 in 2Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on November 30, 2022

PetMed Express, Inc. to Report Q2, 2023 Results on Nov 07, 2022

Now 20% undervalued

Upcoming dividend of US$0.30 per share

First quarter 2023 earnings released: EPS: US$0.14 (vs US$0.22 in 1Q 2022)

Petmed Express, Inc. Declares Quarterly Dividend, Payable on August 19, 2022

PetMed Express, Inc. Announces Executive Changes

PetMed Express, Inc. to Report Q1, 2023 Results on Jul 25, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

Full year 2022 earnings released: EPS: US$1.05 (vs US$1.53 in FY 2021)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on May 27, 2022

PetMed Express, Inc. to Report Q4, 2022 Results on May 09, 2022

PetMed Express, Inc. Appoints Diana Garvis Purcel to Board of Directors, Effective April 4, 2022

Upcoming dividend of US$0.30 per share

PetMed Express, Inc. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS US$0.32 (vs US$0.42 in 2Q 2021)

Independent Director Frank Formica has left the company

First quarter 2022 earnings released: EPS US$0.22 (vs US$0.39 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on May 21, 2021

マネジメント基準チェック /14